China Life’s revenue surges as top insurer ramps up investment in AI, chips and biotech
China Life Insurance, the largest life insurer in China, reported a substantial increase in its first-half financial results. The company's revenue surged by 81.5 percent year-on-year to 434.3 billion yuan (US$64.6 billion), while net profit soared over 228 percent to 134.5 billion yuan. This growth was attributed to diversified business development, refined asset allocation, and robust investment returns. The insurer plans to scale up investments in technology-related sectors, including AI, chips, and biotech, aiming to become a long-term partner for innovative enterprises in these fields.
China Life's significant profit surge, with net profit up 228 percent to 134.5 billion yuan, is less about traditional insurance growth and more about its aggressive pivot into tech investments. The company explicitly states its intent to become a long-term partner for innovative enterprises in AI, chips, and biotech. This reflects a broader trend among major Chinese financial institutions to diversify capital deployment beyond conventional sectors and into strategic, state-backed technology initiatives. The move by China Life, the world's largest life insurer by market value, injects substantial capital into China's tech innovation ecosystem. Vice-president Liu Hui noted that investments in new quality productive forces are a key growth driver. The thing to watch is how effectively a large, state-owned insurer can identify and nurture high-growth tech ventures, and whether its long-term partnership model can truly accelerate innovation in sensitive sectors like chips and AI.
